Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...

ERDA, Utah (KUTV) — Two people were killed on Wednesday after a semi-truck collided with a Corvette near Erda in Tooele County. The crash was first reported just after 10 a.m. on March 25 at the ...

ERDA, Utah — One person was transported to the hospital following a five-vehicle crash in Erda early Tuesday morning. The identity of the person sent to the hospital hasn't been released. According to ...

In a phase 1 study, an erdafitinib intravesical drug-releasing system showed preliminary safety as well as efficacy in NMIBC with FGFR alterations. TAR-210, an erdafitinib intravesical drug-releasing ...

The third opera of Barrie Kosky’s Ring cycle again places the naked ancient earth goddess centre stage in a thoughtful and deft production that boasts an excellent cast and orchestral playing that ...

Johnson & Johnson (J&J) has reported encouraging results from a Phase I study of the investigational intravesical drug-releasing system, Erda-iDRS (erdafitinib). The trial targets patients with ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Johnson & Johnson (NYSE:JNJ) reported encouraging Phase 1 data for Erda-iDRS, an ...

Johnson & Johnson (JNJ) announced on Friday the achievement of a primary safety endpoint in a Phase 1 trial for a drug delivery system designed to administer its bladder cancer therapy erdafitinib, ...

Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the ...

RARITAN, N.J., March 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical ...